Acute Coronary Syndrome

47 %
53 %
Information about Acute Coronary Syndrome
Health & Medicine

Published on March 1, 2014

Author: Bonnieoliver



The presentation explore the facts of Coronary Syndrome and its complications.

Acute Coronary Syndrome (ACS) 3 Aug 2011 Khanittha L,M.D Naresuan University Hospital

Coronary Artery

Hospital Hx PE EKG Ventricular systolic dysfunction (LV/RV) Recurrent ischemia/infarct • Inhospital admission • After discharged ACS Mechanical complication •Myocardial rupture •MR •VSD Electrical instability •VT/VF •Heart Block •Atrial arrhythmia

หัวใจล้มเหลว ล้ามเนื้อหัวใจขาดเลือดซ๊ำ๊า n-hospital admission fter discharged ACS หัวใจเต้นผิด จังหวะ •VT/VF •Heart Block •Atrial arrhythmia ภาวะแทรกซ๊้อนทาง mechanical •Myocardial rupture •MR •VSD

Coronary Artery Disease (CAD) *Acute coronary syndrome *Unstable angina *Acute non ST-elevation myocardial infarction *Acute ST-elevation myocardial infarction *Chronic coronary artery disease : chronic stable angina

Spectrum of CAD/ACS No ST elevation Stable angina Unstable angina ST elevation NSTEMI ACUTE CORONARY SYNDROMES CAD = coronary artery disease; NSTEMI = non-ST-segment elevation myocardial infarction; STEMI = ST-segment elevation myocardial infarction. Source (Photos): Davies MJ. Heart. 2000;83:361-366. STEMI

Pathophysiology of ACS Subtotal artery occlusion Non ST elevation ACS (UA/NSTEMI) Complete total occlusion ST elevation ACS (STEMI)

Structure of thrombus following plaque disruption UA/NSTEMI Non-occlusive thrombus (platelets, some fibrins) STEMI Occlusive thrombus (platelets, fibrins, red cell) Plaque core Intra-plaque thrombus (platelet dominated)

Understanding Myocardial Ischemia Imbalance

Understanding Myocardial Ischemia Decrease O2 Supply Increase Demand Mechanical Obstruction Dec. Oxygenated Blood Flow Increase cardiac output……….. (Thyrotoxicosis) Atheroma Anemia Myocardial Hypertrophy Thrombosis Carboxyhemoglobinemia Spasm Hypotension CAUSING DEC CORONARY PERFUSION PRESSURE Embolus Coronary arteritis Coronary trauma (AS,HTN)

Plaque Fissure or Rupture Platelet Adhesion Platelet Activation Platelet Aggregation Thrombotic Occlusion

Consequence of Acute Coronary Occlusion


Clinical Presentation Of ACS

Focused History • Aid in diagnosis and rule out other causes – Palliative/Provocative factors – Quality of discomfort – Radiation – Symptoms associated with discomfort – Cardiac risk factors – Past medical history -especially cardiac • Reperfusion questions – Timing of presentation – ECG c/w STEMI – Contraindication to fibrinolysis – Degree of STEMI risk

Symptom * Acute chest pain * Nausea/ vomiting * Sweating * Dyspnea * Palpitation * Syncope * Pulmonary edema * Epigastric pain * Post-op hypotension * Oliguria * Acute confusional state * Stroke * Diabetic hyperglycemia state

ACS Clinical Presentation * Substernal chest pain or pressure (>20-30 min) * Localization or radiation to arms, back, throat, jaw * Accompanying features * Dyspnea * Nausea/vomiting * Diaphoresis * Weakness * Atypical: syncope

Risk Factor for Acute Coronary Syndrome *Non-modifiable *Modifiable

Risk Factor *Age Incidence increase with age. *Male gender * Men > premenupausal women * After menupause , incidence is almost same *Family History of IHD

Modifiable Risk Factors •Smoking •Hyperlipidemia •Hypertension •Diabetes mellitus •Lack of exercise •Blood coagulation factors •Personality •Obesity

Targeted Physical Examination *Vital signs *Cardiovascular system *Respiratory system *Abdomen *Neurological status *Recognize factors that increase risk *Hypotension *Tachycardia *Pulmonary rales, JVP, pulmonary edema, *New murmurs/heart sounds *Diminished peripheral pulses *Signs of stroke

Acute coronary syndromes Aortic dissection Esophageal reflux Pneumothorax Chest pain Myocarditis Costochronditis Acute pulmonary embolism Acute pericarditis Psychosomatic

Acute Coronary Syndromes ST-elevation MI Cardiac marker +ve Non-ST elevation ACS Cardiac marker +ve Unstable angina Cardiac marker - ve

*Normal *ST-depression *T-wave inversion *ST-elevation or *LBBB *Repeat EKG when patient is in pain *Continuous ST – segment monitoring

Cardiac Markers

Timing of Release of Various Biomarkers After Acute Myocardial Infarction Anderson, J. L. et al. J Am Coll Cardiol 2007;50:e1-e157 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply.

Cardiac Markers Troponin ( T, I) CK-MB isoenzyme *Very specific and more sensitive *Rises 4-6 hours after injury and than CK *Rises 4-8 hours after injury *May remain elevated for up to two weeks *Can provide prognostic information *Troponin T may be elevated with renal dz, poly/dermatomyositis peaks at 24 hours *Remains elevated 36-48 hours *Positive if CK/MB > 5% of total CK and 2 times normal *Elevation can be predictive of mortality *False positives with exercise, trauma, muscle dz,

Chest pain Non Cardiac Diagnosis – – – – Assess 12 lead ECG Initial assesment Hx PE EKG and EKG monitoring CXR Possible Chronic ACS Stable Angina Goal = 10 min Definite ACS

Chest Pain Suggestive of Ischemia Immediate assessment within 10 Minutes Initial labs and tests *12 lead ECG *Obtain initial cardiac enzymes *Electrolytes, CBC, lipids, BUN/Cr, glucose, Coags *CXR Emergent care  IV access  Cardiac monitoring  Oxygen  Aspirin  Nitrates History & Physical     Establish diagnosis Read ECG Identify complications Assess for reperfusion

แนวทางการรักษาคนไข้ ACS *Prevent plaque rupture : Statins *Decrease O2 need *Decrease platelet activation and aggregation *Open blocked vessel

Acute ST Elevation Myocardial Infarction

Assessments and treatments to consider for patients who present with ACS Initial general treatment (“M O N A C”) *Morphine 2-4 mg q 5-10 min *Oxygen 4 L/min *NTG sublingual or spray, followed by infusion for persistent chest pain *Aspirin 160 -325 mg chew and swallow or/and *Clopidogrel 300mg oral

Specific Treatment : Reperfusion Therapy Fibrinolysis vs primary PCI “Time is muscle”

Treatment of ASTEMI  Open coronary artery within 12 hr  Reperfusion  Fibrinolytic  Primary Therapy agents : Streptokinase, tPA PTCA

Reperfusion Therapy จุดมุ่งหมาย : ให้การวินิจฉัยและรักษาผู้ปวย STEMI ่ อย่างรวดเร็ว * Door to needle time ( หรือ First medical contact-to-needle time) ระยะเวลาที่เริ่มให้ fibrinolytic therapy ควรอยู่ภายใน 30 นาที * Door to balloon time ( หรือ First medical contact-to-balloon time )

Contraindications and Cautions for Fibrinolysis in STEMI • Any prior intracranial hemorrhage • Known structural cerebral vascular lesion Absolute (e.g., arteriovenous malformation) Contraindications • Known malignant intracranial neoplasm (primary or metastatic) • Ischemic stroke within 3 months EXCEPT acute ischemic stroke within 3 hours • Suspected aortic dissection • Active bleeding or bleeding diathesis (excluding menses) • Significant closed-head or facial trauma within 3 months ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction 2004

Contraindications and Cautions for Fibrinolysis in STEMI • History of chronic, severe, poorly controlled Relative hypertension Contraindications • Severe uncontrolled hypertension on presentation (SBP > 180 mm Hg or DBP > 110 mm Hg) • History of prior ischemic stroke greater than 3 months, dementia, or known intracranial pathology not covered in contraindications • Traumatic or prolonged (> 10 minutes) CPR or major surgery (< 3 weeks) ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction 2004

การรัก ษาผู้ป ่ว ย ST-Elevation MI หรืelevation หรือ new LBBB อ New LBBB ST > 12 hour < 12 hour Eligible for reperfusion Rx Thrombolytic is contra-indicated 1° PCI Thrombolytic Rx : Streptokinase : rt-PA Not candidate for reperfusion Rx Other medical treatment B-blocker ACEI / ARB Nitrate Statin Persistent symptom No Yes Consider reperfusion Rx


Door to Needle Time and Mortality In hospital mortality (%) 20 18 16 14 12 10 8 6 4 2 0 18.1 14.14 10.3 6.3 4.3 0-30 16 31-60 Door to Balloon Time and Mortality 61-90 >90 no thrombolysis 14.1 14 12 10 10 8 6 9.1 7 5.6 4 2 0 <60 61-90 91-120 120-180 >180 Thai ACS registry

Comparison of Approved Fibrinolytic Drugs Feature SK t-PA Fibrin-specific - ++ Half-life (minutes) 20 5 Antigencity Y N 90 minutes patency 60 84 Rate of ICH 0.34 0.69 Requires concomitant heparin +/- Y Weight adjusted dosing N Y Dose 1.5 mL units IV over 60 minutes 15 mg IV /1-2min 0.75 mg/kg IV/30 min (max 50 mg) 0.5 mg/kg IV/60 min (max 35 mg) SK Bolus administration N N Cost per dose (Baht) 9,606 49,857 50

ACS : Unstable angina or NSTEMI

การแบ่งผู้ป่วยทีมาด้วย chest pain ตามปัจจัยเสี่ยงถึงความน่าจะ ่ เป็นโรคหัวใจโคโรนารี (CAD)ตามลักษณะทางคลินิก และ EKG แรกรับ

ปัจจัยเสี่ยงต่อการตาย และ nonfatal MI ในผู้ป่วยทีมี chest pain ่ สงสัย ischemia


ACS : NSTEM or UA Fibrinolytic Antithrombin UFH, LMWH Stabilized Severe stenosis Antiplatelets Subtotal occlusion ASA, clopidogrel, G2b3a inhibitors

Assessments and treatments to consider for patients who present with ACS Initial general treatment (“ M O N A C ”) *M orphine 2-4 mg q 5-10 min *O xygen 4 L/min *N TG sublingual or spray, followed by infusion for persistent chest pain *A spirin 160 -325 mg chew and swallow or/and *C lopidogrel 300mg oral


Initial Conservative Strategy : Early Hospital Care *ASA; clopidogrel if intolerant (I, A) *Anticoagulant therapy should be added to antiplatelet therapy as soon as possible after presentation (I, A) *Enoxaparin or UFH (I, A) *Fondaparinux (I, B) *Enoxaparin or fondaparinux preferable (IIa, B) *Initiate clopidogrel, loading dose + maintenance dose (I, A) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

Adjunctive Therapies * Beta-blocker *ถ้าไม่มีข้อห้าม * IV nitroglycerine *สำาหรับ recurrent ischemia, large anterior MI, heart failure, antihypertensive effects * ACE inhibitor *โดยเฉพาะ large anterior wall MI, heart failure ควรให้ หลัง 24 ชม.

Secondary Prevention and Long Term Management Goals Smoking Goal: Complete Cessation Recommendations • Assess tobacco use. • Strongly encourage patient and family to stop smoking and to avoid secondhand smoke. • Provide counseling, pharmacological therapy (including nicotine replacement and bupropion), and formal smoking cessation programs as appropriate. 61

Secondary Prevention and Long Term Management Goals Blood pressure control: Goal: < 140/90 mm Hg or <130/80 mm Hg if chronic kidney disease or diabetes Recommendations If blood pressure is 120/80 mm Hg or greater: • Initiate lifestyle modification (weight control, physical activity, alcohol moderation, moderate sodium restriction, and emphasis on fruits, vegetables, and low-fat dairy products) in all patients. If blood pressure is 140/90 mm Hg or greater or 130/80 mm Hg or greater for individuals with chronic kidney disease or diabetes: • Add blood pressure-reducing medications, emphasizing the use of beta-blockers and inhibitors of the renin-angiotensinaldosterone system. 62

Secondary Prevention and Long Term Management Goals Physical activity: Minimum goal: 30 minutes 3 to 4 days per week; Optimal daily Recommendations • Assess risk, preferably with exercise test, to guide prescription. • Encourage minimum of 30 to 60 minutes of activity, preferably daily but at least 3 or 4 times weekly (walking, jogging, cycling, or other aerobic activity) supplemented by an increase in daily lifestyle activities (e.g., walking breaks at work, gardening, household work). • Cardiac rehabilitation programs are recommended for patients with STEMI. 63

Secondary Prevention and Long Term Management Goals Lipid management: (TG less than 200 mg/dL) Primary goal: LDL-C << than 100 mg/dL Recommendations • Start dietary therapy in all patients (< 7% of total calories as saturated fat and < 200 mg/d cholesterol). Promote physical activity and weight management. Encourage increased consumption of omega-3 fatty acids. • Assess fasting lipid profile in all patients, preferably within 24 hours of STEMI. Add drug therapy according to the following guide: LDL-C < 100 mg/dL (baseline or on treatment): Statins should be used to lower LDL-C. LDL-C ≥ 100 mg/dL (baseline or on treatment): Intensify LDL-C–lowering therapy with drug treatment, giving preference to statins. 64

Secondary Prevention and Long Term Management Goals Lipid management: (TG 200 mg/dL or greater) Primary goal: Non–HDL-C << 130 mg/dL Recommendations If TGs are ≥ 150 mg/dL or HDL-C is < 40 mg/dL: Emphasize weight management and physical activity. Advise smoking cessation. If TG is 200 to 499 mg/dL: After LDL-C–lowering therapy, consider adding fibrate or niacin. If TG is ≥ 500 mg/dL: Consider fibrate or niacin before LDL-C–lowering therapy. Consider omega-3 fatty acids as adjunct for high TG. 65

Secondary Prevention and Long Term Management Goals Weight management: Goal: BMI 18.5 to 24.9 kg/m2 Waist circumference: Women: < 35 in. Men: < 40 in. Recommendations Calculate BMI and measure waist circumference as part of evaluation. Monitor response of BMI and waist circumference to therapy. Start weight management and physical activity as appropriate. Desirable BMI range is 18.5 to 24.9 kg/m2. If waist circumference is ≥ 35 inches in women or ≥ 40 inches in men, initiate lifestyle changes and treatment strategies for metabolic syndrome. 66

Secondary Prevention and Long Term Management Goals Diabetes management: Goal: HbA1c < 7% Recommendations Appropriate hypoglycemic therapy to achieve near-normal fasting plasma glucose, as indicated by HbA1c. Treatment of other risk factors (e.g., physical activity, weight management, blood pressure, and cholesterol management). 67

Management Strategies in Acute Coronary syndrome(ACS) Symptoms of Acute Coronary Syndrome ST elevation (STEMI) EKG Reperfusion approach All patients 1. ASA 1. Anti-ischemic medications 2. Heparin(UFH or LMWH) Beta-blocker 3. Clopidogrel Nitrated 4. Choose reperfusion method+/-Ca++ channel blocker a. Fibrinolytic drug 2. General measures b. Primary PCI Oxygen Pain control (morphine) 3. Additional therapies ACE inhibitor Statin No ST elevation (UA/NSTEMI) Antithrombotic approach 1. ASA 2. Heparin(UFH or LMWH) 3. Clopidogrel 4. For high risk patients GP IIb/IIIa inhibitor Proceed to cathlab

“ABCDE” A- antiplatelets, ACE-I B- beta-blocker, blood pressure control C- cholesterol lowering, cigarette smoking cessation D- diet, diabetes management E- exercise

Add a comment

Related presentations

Related pages

Acute coronary syndrome - Wikipedia, the free encyclopedia

Acute coronary syndrome (ACS) is a syndrome (set of signs and symptoms) due to decreased blood flow in the coronary arteries such that part of the heart ...
Read more

Akutes Koronarsyndrom – Wikipedia

Der Begriff akutes Koronarsyndrom (ACS; Acute coronary syndrome) beschreibt ein Spektrum von Herz-Kreislauf-Erkrankungen, die durch den Verschluss oder die ...
Read more

Acute Coronary Syndrome: Practice Essentials, Background ...

Acute coronary syndrome (ACS) refers to a spectrum of clinical presentations ranging from those for ST-segment elevation myocardial infarction ...
Read more

Acute Coronary Syndrome - American Heart Association

So you’ve never heard of an acute coronary syndrome. But what about heart attack, or unstable angina? Those well-known conditions are both acute coronary ...
Read more

Acute coronary syndromes | The BMJ

Acute coronary syndromes, or “heart attacks,” include unstable angina and acute myocardial infarction. The latter is further classified according to ...
Read more

Acute Coronary Syndromes: Diagnosis and Management, Part I

The term acute coronary syndrome (ACS) refers to any group of clinical symptoms compatible with acute myocardial ischemia and includes unstable angina (UA ...
Read more

Acute Coronary Syndrome. Heart condition health ...

Acute coronary syndrome is a term given by doctors to various heart conditions, including a heart attack and unstable angina. These conditions are due to ...
Read more

Overview - Acute coronary syndrome - Mayo Clinic

Acute coronary syndrome — Overview covers symptoms, causes and treatment of this condition that causes low blood flow to the heart.
Read more

Acute Coronary Syndrome | Doctor | Patient

Acute coronary syndrome (ACS) is a medical emergency and requires immediate hospital admission. Acute coronary syndromes are now classified mainly on the...
Read more

Acute coronary syndromes | The Heart Foundation

The Heart Foundation saves lives and improves health through funding world-class cardiovascular research, guidelines for health professionals, informing ...
Read more